Results 21 to 30 of about 162,270 (298)
Challenges Faced by States and the WHO in Efficiently Regulating the Use of mRNA Vaccines
Medical Sciences Forum, 2023 According to the World Health Organization (WHO), there is no formal regulatory guidance specifically for mRNA-based vaccines. However, the WHO provides information and regulatory considerations regarding key aspects of the manufacture and quality ...
Rabaï Bouderhem
doaj +1 more source
mRNA Vaccine Platform: mRNA Production and Delivery
Russian Journal of Bioorganic Chemistry, 2023 Vaccination is the most efficient way to prevent infectious diseases. mRNA-based vaccines is a new approach to vaccine development, which have several very useful advantages over other types of vaccines. Since mRNA encodes only the target antigen there is no potential risk of infection as in the case with attenuated or inactivated pathogens.
Litvinova, V. R. +3 more
openaire +2 more sources
Updated Considerations for the Immunopharmacological Aspects of the “Talented mRNA Vaccines”
Vaccines, 2023 Messenger RNA (mRNA) vaccines belong to a new class of medications, RNA therapeutics, including both coding and non-coding RNAs. The use of mRNA as a therapy is based on the biological role of mRNA itself, namely its translation into a functional protein.
Cristiana Perrotta +6 more
doaj +1 more source
Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
Clinical Case Reports, 2022 AbstractIn this case report, we presented a case of myocarditis as a rare complication that developed after Covid mRNA‐1273 vaccine. Cases of post‐vaccine myocarditis usually progress with mild symptoms. However, it should be a situation that healthcare workers should keep in mind, that myocarditis may develop after vaccination.
Suresh Babu Chellapandian +4 more
openaire +3 more sources
Delivery Strategies for mRNA Vaccines [PDF]
Pharmaceutical Medicine, 2022 The therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle-based small interfering RNA (siRNA) therapy reach the market with the United States Food and Drug Administration (FDA) approval of patisiran (Onpattro™) for hereditary ATTR ...
Sivakumar Ramachandran +2 more
openaire +2 more sources
Emerging trends of research on mRNA vaccines: A co-citation analysis
Human Vaccines & Immunotherapeutics, 2022 This study was designed to evaluate the emerging trends of research on mRNA vaccines. Altogether 3056 research articles related to mRNA vaccines published since 2010 were retrieved from the Web of Science database, based on which a co-citation analysis ...
Juan Chen +4 more
doaj +1 more source
Vaccines, 2021 This systematic review and meta-analysis was conducted to compare the safety and efficacy of 2019 novel coronavirus disease (COVID-19) vaccines according to vaccine platform and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection ...
Yu-Jing Fan +2 more
doaj +1 more source
RNA Vaccine: novel approach for cancer treatment [PDF]
, 2011 Cancer is still an unsolved puzzle and a major cause of mortality and morbidity in the world. Today, about one in every thousand people is dying due to cancer. No effective agent has yet been found which can cure cancer in its metastatic stage.
Kanika Bhalla +2 more
core +2 more sources
Have mRNA vaccines sentenced DNA vaccines to death?
Expert Review of Vaccines, 2023 Introduction After receiving emergency approval during the COVID-19 pandemic, mRNA vaccines have taken center stage in the quest to enhance future vaccination strategies for both infectious diseases and cancer.
Alberto Cagigi, Bruno Douradinha
doaj +1 more source
Molecular signatures of a TLR4 agonist-adjuvanted HIV-1 vaccine candidate in humans [PDF]
, 2018 Systems biology approaches have recently provided new insights into the mechanisms of action of human vaccines and adjuvants. Here, we investigated early transcriptional signatures induced in whole blood of healthy subjects following vaccination with a ...
Anderson, J +7 more
core +2 more sources